Todd Fago, MD
Family Medicine · York, NENPI 1730195744
Payments from drug & device makers
Across 186 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$216
- Novo Nordisk$190
- Astellas Pharma US Inc$180
- Johnson & Johnson$100
- Bayer$97
- plus $794 from 28 others
What the payments were for
- Food & beverage$2,93699%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 82 | $1,376 |
| Amgen | 18 | $216 |
| Novo Nordisk | 14 | $190 |
| Astellas Pharma US Inc | 6 | $180 |
| Johnson & Johnson | 6 | $100 |
| Bayer | 7 | $97 |
| Lilly USA, LLC | 5 | $70 |
| Pfizer | 5 | $67 |
| Organon | 4 | $58 |
| Philips North America LLC | 4 | $49 |
| Exact Sciences | 3 | $43 |
| Novartis | 3 | $43 |
| GSK | 3 | $39 |
| Eisai Inc. | 2 | $35 |
| Merck | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Itamar Medical Inc | 1 | $28 |
| Mylan Specialty L.p. | 2 | $27 |
| AstraZeneca | 2 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Optinose US, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Seqirus USA Inc | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| CSL Behring | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $12 |
How this compares
$2,952 in reported general payments places this provider in the 80th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 82 | $78,612 |
| RexultiBrexpiprazole | 31 | $46,820 |
| EliquisApixaban | 76 | $46,551 |
| JardianceEmpagliflozin | 66 | $43,048 |
| MounjaroTirzepatide | 38 | $41,428 |
| RybelsusSemaglutide | 26 | $32,249 |
| JanuviaSitagliptin Phosphate | 42 | $30,949 |
| OzempicSemaglutide | 21 | $22,823 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $19,766 |
| MyrbetriqMirabegron | 45 | $16,111 |
| FarxigaDapagliflozin Propanediol | 23 | $14,990 |
| LinzessLinaclotide | 25 | $13,754 |
| XareltoRivaroxaban | 21 | $11,278 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $10,708 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $9,236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $70 | $120,040120 claims |
| PfizerEliquis, Abrysvo, Premarin | $67 | $58,584108 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $12 | $57,12093 claims |
| Novo NordiskRybelsus, Ozempic | $190 | $55,07347 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $22 | $46,82031 claims |
| MerckJanuvia | $33 | $30,94942 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $39 | $27,77774 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $24 | $24,22637 claims |
| Astellas Pharma US IncMyrbetriq | $180 | $16,11145 claims |
| AbbVieLinzess | $1,376 | $13,75425 claims |
| Johnson & JohnsonXarelto | $100 | $11,27821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 981 family medicine providers in Nebraska.
Other family medicine in York
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.